Evidence map›Paper›PMID 32857339›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

Identification of a novel immune prognostic model in gastric cancer.

Y Li, X He, L Fan, X Zhang, Y Xu, X Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Research progress on the expression characteristics, biological functions, and therapeutic potential of NOX4 in malignant tumors: a functional perspective.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Y LiCancer Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, China.
X HeCancer Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, China.
L FanCancer Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, China.
X ZhangCancer Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, China.
Y XuCancer Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, China.
X XuCancer Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, China. doctorxu120@aliyun.com.ORCID http://orcid.org/0000-0002-4240-5378

Funding

National Natural Science Foundation of China 31971166
6 · The paper itself

Abstract

purposeThe tumor immune microenvironment (TIME) is now considered as an important factor during gastric cancer (GC) development. This study identified a novel immune-related risk model for predicting prognosis and assessing the immune status of GC patients.

methodsTranscriptomic data were obtained from the TCGA database. The differential expressed immune-related genes (IRGs) were identified through the ImmPort portal. Enrichment analysis was performed to explore the potential molecular mechanism of these IRGs. By the Cox regression analysis, we constructed the immune prognostic model. Then, the association between the model and the immune microenvironment was estimated. The model was validated in the GSE84433 dataset.

resultsTotally, we identified 222 differentially expressed IRGs. These IRGs were closely correlated with immune response and immune signaling pathways. Through the Cox regression analysis, we developed the immune prognostic model based on the expression of seven IRGs (CXCL3, NOX4, PROC, FAM19A4, RNASE2, IGHD2-15, CGB5). Patients were stratified into two groups according to immune-related risk scores. Survival analysis indicated that the prognosis of high-risk patients was poorer than low-risk patients. Moreover, the immune-related risk score was an independent prognostic biomarker. More importantly, we found that the infiltration level of immunosuppressive cells and the expression of inhibitory immune checkpoints were higher in high-risk patients. The immune microenvironment tended to be a suppressive status in patients with high-risk scores.

conclusionThis study demonstrated that our model had predictive value for prognosis and the TIME in GC. It might be a robust tool to improve personalized patient management.

Indexed as

Models, ImmunologicalChemokines, CXCCytokinesDatabases, GeneticDisease ProgressionDwarfism, PituitaryEosinophil-Derived NeurotoxinGene ExpressionHumansImmune Checkpoint ProteinsImmune ToleranceImmunityNADPH Oxidase 4Neoplastic Stem CellsPrognosisRegression AnalysisChemokines, CXCCXCL3 protein, humanCytokinesEosinophil-Derived NeurotoxinImmune Checkpoint ProteinsNADPH Oxidase 4NOX4 protein, humanRNASE2 protein, humanTAFA4 protein, humanGastric cancerImmune-related geneModelPrognosisTumor immune microenvironment

Identifiers

PMID32857339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.